Christopher Crean

Christopher Crean has worked in the pharmaceutical industry since 1995, beginning their career as an Inhalation Toxicologist at MPI Research. Christopher then moved to GlaxoWellcome as a Scientist in 1997, before joining Icagen as a Research Scientist in 1999. In 2001, they took on the role of Associate Director Drug Disposition and Analysis at Inspire Pharmaceuticals, where they developed the technical group focused on DMPK and Clinical Pharmacology and built out the Mass Spectrometry lab and functions. In 2009, they became the Director of Preclinical, Clinical Pharmacology and Pharmacokinetics at Valeant Pharmaceuticals, where they were responsible for select project strategy and leadership, clinical pharmacology and pharmacokinetic functions and scientific interactions with regulatory authorities within the therapeutic areas of Neurosciences, Ophthalmology and Dermatology. In 2013, they assumed the role of President at Chatham Biopharma Consulting, LLC, and also became a Sr. Consultant, Translational Research and Clinical PK at Nuventra Pharma Sciences. In 2015, they co-founded 1st Order Pharmaceuticals, Inc., and served as President and Chief Science Officer. In 2018, they became the CEO and Principal Consultant at Xyzagen, Inc.

Christopher Crean received their Master of Science in Clinical Research from Campbell University and their Bachelor of Science in Biochemistry from Michigan State University.